Natika H Halil on providing emergency contraception to under 16s

Recently the UK’s press went into overdrive reporting on the recent change in emergency contraceptive pill ellaOne’s product licence—now available to buy over the counter for women of “all reproductive ages,” and therefore including under 16s. Of course levonorgestrel was already available to under 16s in pharmacies in many areas through patient group directions. In […]

Read More…

Sioned Gwyn on sexism and women in medicine

Sir Tim Hunt, British biochemist and Nobel Laureate, had until recently enjoyed relative anonymity outside of scientific fields. Recently, at an international conference of science journalists in Seoul, he was invited to speak at a meeting for women in science and delivered as part of his speech an extraordinarily ill judged few sentences which have […]

Read More…

Karsten Juhl Jørgensen: Why do five recent reports on breast screening reach conflicting conclusions?

Since 2012, five collaborative efforts to quantify the benefits and harms of breast screening have been published. These are the UK Independent Review, the EUROSCREEN Working Group series (both 2012), the Swiss Medical Board report (2014), the updated IARC/WHO Handbook, and a report from the Research Council of Norway (both 2015). The approach to put […]

Read More…

Adam Smith: The life and legacy of oncology PROMs

Since the 1980s, patient reported outcomes measures (PROMs) have been incorporated in cancer clinical trials providing invaluable information about symptoms, functioning, and quality of life from the patients’ perspective. In 2009, the US Food and Drug Administration (FDA), issued industry guidance on the use of PROMs in product label claims [1]. The guidance stressed the […]

Read More…